



Tom the Amazing <tomgle@gmail.com>

Health Record from FollowMyHealth®

FollowMyHealth <noreply@followmyhealth.com>
To: tomgle@gmail.com

Wed, Feb 1, 2023 at 11:33 AM

Name: Thomas F Glembocki
Date of Birth: 06-Nov-1946
Gender Identity: Male

Results

Order: Lipid Panel (LDL:HDL ratio) (80061) Ordered On: 10/04/2018

Notes:

PATIENT WAS FASTING
PERFORMED BY: BN LabCorp Burlington
[1447 York Court](#)
[Burlington NC 272153361](#)
8007624344

Name	Resulted On	Value	Units	Range	Source
Cholesterol, Total	10/17/2018	158	mg/dL	100-199	Raleigh Medical Group, P.A.
Triglycerides	10/17/2018	83	mg/dL	0-149	Raleigh Medical Group, P.A.
HDL Cholesterol	10/17/2018	39	mg/dL	>39	Raleigh Medical Group, P.A.
VLDL Cholesterol Cal	10/17/2018	17	mg/dL	5-40	Raleigh Medical Group, P.A.
LDL/HDL Ratio	10/17/2018	2.6	ratio	0.0-3.6	Raleigh Medical Group, P.A.

Notes:

LDL/HDL Ratio		
	Men	Women
1/2 Avg.Risk	1.0	1.5
Avg.Risk	3.6	3.2
2X Avg.Risk	6.2	5.0
3X Avg.Risk	8.0	6.1

LDL/HDL Ratio		
	Men	Women
1/2 Avg.Risk	1.0	1.5
Avg.Risk	3.6	3.2
2X Avg.Risk	6.2	5.0
3X Avg.Risk	8.0	6.1

LDL Cholesterol Calc 10/17/2018 102 mg/dL 0-99 Raleigh Medical Group, P.A.

Order: Lipid Panel (LDL:HDL ratio) (80061) Ordered On: 03/11/2014

Notes:

PERFORMED BY: 01 LabCorp Burlington
[1447 York Court](#)
[Burlington NC 272153361](#)
8007624344

Name	Resulted On	Value	Units	Range	Source
Cholesterol, Total	3/15/2014	176	mg/dL	100-199	Raleigh Medical Group, P.A.
Triglycerides	3/15/2014	112	mg/dL	0-149	Raleigh Medical Group, P.A.
VLDL Cholesterol Cal	3/15/2014	22	mg/dL	5-40	Raleigh Medical Group, P.A.
LDL/HDL Ratio	3/15/2014	3.1	ratio units	0.0-3.6	Raleigh Medical Group, P.A.
HDL Cholesterol	3/15/2014	38	mg/dL	>39	Raleigh Medical Group, P.A.

Notes:

According to ATP-III Guidelines, HDL-C >59 mg/dL is considered a negative risk factor for CHD.

Name	Resulted On	Value	Units	Range	Source
According to ATP-III Guidelines, HDL-C >59 mg/dL is considered a negative risk factor for CHD.					
LDL Cholesterol Calc	3/15/2014	116	mg/dL	0-99	Raleigh Medical Group, P.A.

Order: Lipid Panel (LDL:HDL ratio) (80061) Ordered On: 10/09/2019

Notes:

PATIENT WAS FASTING
 PERFORMED BY: BN LabCorp Burlington
[1447 York Court](#)
[Burlington NC 272153361](#)
 8007624344

Name	Resulted On	Value	Units	Range	Source
Cholesterol, Total	10/22/2019	198	mg/dL	100-199	Raleigh Medical Group, P.A.
Triglycerides	10/22/2019	131	mg/dL	0-149	Raleigh Medical Group, P.A.
HDL Cholesterol	10/22/2019	38	mg/dL	>39	Raleigh Medical Group, P.A.
VLDL Cholesterol Cal	10/22/2019	26	mg/dL	5-40	Raleigh Medical Group, P.A.
LDL/HDL Ratio	10/22/2019	3.5	ratio	0.0-3.6	Raleigh Medical Group, P.A.

Notes:

LDL/HDL Ratio		
Men	Women	
1/2 Avg.Risk	1.0	1.5
Avg.Risk	3.6	3.2
2X Avg.Risk	6.2	5.0
3X Avg.Risk	8.0	6.1
LDL/HDL Ratio		
Men	Women	
1/2 Avg.Risk	1.0	1.5
Avg.Risk	3.6	3.2
2X Avg.Risk	6.2	5.0
3X Avg.Risk	8.0	6.1

LDL Cholesterol Calc	10/22/2019	134	mg/dL	0-99	Raleigh Medical Group, P.A.
----------------------	------------	-----	-------	------	-----------------------------

Order: CBC WITH DIFF/PLT COUNT/AUTOMATED (85025) Ordered On: 03/22/2016

Notes:

PATIENT WAS FASTING
 PERFORMED BY: BN LabCorp Burlington
[1447 York Court](#)
[Burlington NC 272153361](#)
 8007624344

Name	Resulted On	Value	Units	Range	Source
WBC	4/1/2016	5.4	x10E3/uL	3.4-10.8	Raleigh Medical Group, P.A.
RBC	4/1/2016	4.69	x10E6/uL	4.14-5.80	Raleigh Medical Group, P.A.
Hemoglobin	4/1/2016	14.8	g/dL	12.6-17.7	Raleigh Medical Group, P.A.
Hematocrit	4/1/2016	42.8	%	37.5-51.0	Raleigh Medical Group, P.A.
MCV	4/1/2016	91	fL	79-97	Raleigh Medical Group, P.A.
MCH	4/1/2016	31.6	pg	26.6-33.0	Raleigh Medical Group, P.A.
MCHC	4/1/2016	34.6	g/dL	31.5-35.7	Raleigh Medical Group, P.A.
RDW	4/1/2016	13.6	%	12.3-15.4	Raleigh Medical Group, P.A.
Platelets	4/1/2016	252	x10E3/uL	150-379	Raleigh Medical Group, P.A.
Neutrophils	4/1/2016	54	%		Raleigh Medical Group, P.A.
Lymphs	4/1/2016	31	%		Raleigh Medical Group, P.A.
Monocytes	4/1/2016	13	%		Raleigh Medical Group, P.A.
Eos	4/1/2016	2	%		Raleigh Medical Group, P.A.
Basos	4/1/2016	0	%		Raleigh Medical Group, P.A.
Neutrophils (Absolute)	4/1/2016	2.9	x10E3/uL	1.4-7.0	Raleigh Medical Group, P.A.
Lymphs (Absolute)	4/1/2016	1.7	x10E3/uL	0.7-3.1	Raleigh Medical Group, P.A.
Monocytes(Absolute)	4/1/2016	0.7	x10E3/uL	0.1-0.9	Raleigh Medical Group, P.A.
Eos (Absolute)	4/1/2016	0.1	x10E3/uL	0.0-0.4	Raleigh Medical Group, P.A.
Baso (Absolute)	4/1/2016	0.0	x10E3/uL	0.0-0.2	Raleigh Medical Group, P.A.

Name	Resulted On	Value	Units	Range	Source
Immature Granulocytes	4/1/2016	0	%		Raleigh Medical Group, P.A.
Immature Grans (Abs)	4/1/2016	0.0	x10E3/uL	0.0-0.1	Raleigh Medical Group, P.A.

Order: Metabolic Panel (14), Comprehensive w/o GFR (80053) Ordered On: 10/04/2018

Notes:

PATIENT WAS FASTING
 PERFORMED BY: BN LabCorp Burlington
[1447 York Court](#)
[Burlington NC 272153361](#)
 8007624344

Name	Resulted On	Value	Units	Range	Source
Glucose	10/17/2018	90	mg/dL	65-99	Raleigh Medical Group, P.A.
BUN	10/17/2018	14	mg/dL	8-27	Raleigh Medical Group, P.A.
Creatinine	10/17/2018	1.08	mg/dL	0.76-1.27	Raleigh Medical Group, P.A.
BUN/Creatinine Ratio	10/17/2018	13		10-24	Raleigh Medical Group, P.A.
Potassium	10/17/2018	3.7	mmol/L	3.5-5.2	Raleigh Medical Group, P.A.
Carbon Dioxide, Total	10/17/2018	25	mmol/L	20-29	Raleigh Medical Group, P.A.
Calcium	10/17/2018	9.9	mg/dL	8.6-10.2	Raleigh Medical Group, P.A.
Protein, Total	10/17/2018	6.9	g/dL	6.0-8.5	Raleigh Medical Group, P.A.
Albumin	10/17/2018	4.4	g/dL	3.5-4.8	Raleigh Medical Group, P.A.
Globulin, Total	10/17/2018	2.5	g/dL	1.5-4.5	Raleigh Medical Group, P.A.
A/G Ratio	10/17/2018	1.8		1.2-2.2	Raleigh Medical Group, P.A.
Bilirubin, Total	10/17/2018	0.6	mg/dL	0.0-1.2	Raleigh Medical Group, P.A.
Sodium	10/17/2018	133	mmol/L	134-144	Raleigh Medical Group, P.A.
Chloride	10/17/2018	93	mmol/L	96-106	Raleigh Medical Group, P.A.
Alkaline Phosphatase	10/17/2018	66	IU/L	39-117	Raleigh Medical Group, P.A.
AST (SGOT)	10/17/2018	19	IU/L	0-40	Raleigh Medical Group, P.A.
ALT (SGPT)	10/17/2018	15	IU/L	0-44	Raleigh Medical Group, P.A.

Order: Metabolic Panel (14), Comprehensive w/o GFR (80053) Ordered On: 03/22/2016

Notes:

PATIENT WAS FASTING
 PERFORMED BY: BN LabCorp Burlington
[1447 York Court](#)
[Burlington NC 272153361](#)
 8007624344

Name	Resulted On	Value	Units	Range	Source
Glucose, Serum	4/1/2016	88	mg/dL	65-99	Raleigh Medical Group, P.A.
BUN	4/1/2016	11	mg/dL	8-27	Raleigh Medical Group, P.A.
Creatinine, Serum	4/1/2016	1.13	mg/dL	0.76-1.27	Raleigh Medical Group, P.A.
BUN/Creatinine Ratio	4/1/2016	10		10-22	Raleigh Medical Group, P.A.
Sodium, Serum	4/1/2016	135	mmol/L	134-144	Raleigh Medical Group, P.A.
Potassium, Serum	4/1/2016	4.7	mmol/L	3.5-5.2	Raleigh Medical Group, P.A.
Carbon Dioxide, Total	4/1/2016	25	mmol/L	18-29	Raleigh Medical Group, P.A.
Calcium, Serum	4/1/2016	9.8	mg/dL	8.6-10.2	Raleigh Medical Group, P.A.
Protein, Total, Serum	4/1/2016	7.1	g/dL	6.0-8.5	Raleigh Medical Group, P.A.
Albumin, Serum	4/1/2016	4.6	g/dL	3.6-4.8	Raleigh Medical Group, P.A.
Globulin, Total	4/1/2016	2.5	g/dL	1.5-4.5	Raleigh Medical Group, P.A.
A/G Ratio	4/1/2016	1.8		1.1-2.5	Raleigh Medical Group, P.A.
Chloride, Serum	4/1/2016	96	mmol/L	97-108	Raleigh Medical Group, P.A.
Bilirubin, Total	4/1/2016	0.8	mg/dL	0.0-1.2	Raleigh Medical Group, P.A.
Alkaline Phosphatase, S	4/1/2016	60	IU/L	39-117	Raleigh Medical Group, P.A.
AST (SGOT)	4/1/2016	23	IU/L	0-40	Raleigh Medical Group, P.A.
ALT (SGPT)	4/1/2016	21	IU/L	0-44	Raleigh Medical Group, P.A.

Order: CBC WITH DIFF/PLT COUNT/AUTOMATED (85025) Ordered On: 10/09/2019

Notes:

PATIENT WAS FASTING
 PERFORMED BY: BN LabCorp Burlington
 1447 York Court
 Burlington NC 272153361
 8007624344

Name	Resulted On	Value	Units	Range	Source
WBC	10/22/2019	5.5	x10E3/uL	3.4-10.8	Raleigh Medical Group, P.A.
RBC	10/22/2019	4.56	x10E6/uL	4.14-5.80	Raleigh Medical Group, P.A.
Hemoglobin	10/22/2019	14.0	g/dL	13.0-17.7	Raleigh Medical Group, P.A.
Hematocrit	10/22/2019	41.1	%	37.5-51.0	Raleigh Medical Group, P.A.
MCV	10/22/2019	90	fL	79-97	Raleigh Medical Group, P.A.
MCH	10/22/2019	30.7	pg	26.6-33.0	Raleigh Medical Group, P.A.
MCHC	10/22/2019	34.1	g/dL	31.5-35.7	Raleigh Medical Group, P.A.
RDW	10/22/2019	12.4	%	12.3-15.4	Raleigh Medical Group, P.A.
Platelets	10/22/2019	213	x10E3/uL	150-450	Raleigh Medical Group, P.A.
Neutrophils	10/22/2019	52	%	Not Estab.	Raleigh Medical Group, P.A.
Lymphs	10/22/2019	34	%	Not Estab.	Raleigh Medical Group, P.A.
Monocytes	10/22/2019	10	%	Not Estab.	Raleigh Medical Group, P.A.
Eos	10/22/2019	3	%	Not Estab.	Raleigh Medical Group, P.A.
Basos	10/22/2019	1	%	Not Estab.	Raleigh Medical Group, P.A.
Neutrophils (Absolute)	10/22/2019	2.8	x10E3/uL	1.4-7.0	Raleigh Medical Group, P.A.
Lymphs (Absolute)	10/22/2019	1.9	x10E3/uL	0.7-3.1	Raleigh Medical Group, P.A.
Monocytes(Absolute)	10/22/2019	0.6	x10E3/uL	0.1-0.9	Raleigh Medical Group, P.A.
Eos (Absolute)	10/22/2019	0.2	x10E3/uL	0.0-0.4	Raleigh Medical Group, P.A.
Baso (Absolute)	10/22/2019	0.0	x10E3/uL	0.0-0.2	Raleigh Medical Group, P.A.
Immature Granulocytes	10/22/2019	0	%	Not Estab.	Raleigh Medical Group, P.A.
Immature Grans (Abs)	10/22/2019	0.0	x10E3/uL	0.0-0.1	Raleigh Medical Group, P.A.

Order: Verbal Add-on Ordered On: 12/22/2011

Notes:

PATIENT WAS FASTING
 PERFORMED BY: BN LabCorp Burlington
 1447 York Court
 Burlington NC 272153361
 8007624344

Name	Resulted On	Value	Units	Range	Source
Verbal Add-on	12/28/2011	Comment			Raleigh Medical Group, P.A.

Notes:

This report has been generated by your request for additional testing.
 The additional request may have required some testing to be repeated.
 Because of analytic variability, the results may not correspond exactly to the previous report. Interpret these results appropriately.

This report has been generated by your request for additional testing.
 The additional request may have required some testing to be repeated.
 Because of analytic variability, the results may not correspond exactly to the previous report. Interpret these results appropriately.

Order: CBC WITH DIFF/PLT COUNT/AUTOMATED (85025) Ordered On: 12/20/2011

Notes:

PATIENT WAS FASTING
 PERFORMED BY: BN LabCorp Burlington
 1447 York Court
 Burlington NC 272153361
 8007624344

Name	Resulted On	Value	Units	Range	Source
WBC	12/23/2011	6.9	x10E3/uL	4.0-10.5	Raleigh Medical Group, P.A.
RBC	12/23/2011	4.69	x10E6/uL	4.10-5.60	Raleigh Medical Group, P.A.
Hemoglobin	12/23/2011	14.2	g/dL	12.5-17.0	Raleigh Medical Group, P.A.
Hematocrit	12/23/2011	41.9	%	36.0-50.0	Raleigh Medical Group, P.A.
MCV	12/23/2011	89	fL	80-98	Raleigh Medical Group, P.A.

Name	Resulted On	Value	Units	Range	Source
MCH	12/23/2011	30.3	pg	27.0-34.0	Raleigh Medical Group, P.A.
MCHC	12/23/2011	33.9	g/dL	32.0-36.0	Raleigh Medical Group, P.A.
RDW	12/23/2011	13.0	%	11.7-15.0	Raleigh Medical Group, P.A.
Platelets	12/23/2011	240	x10E3/uL	140-415	Raleigh Medical Group, P.A.
Neutrophils	12/23/2011	55	%	40-74	Raleigh Medical Group, P.A.
Lymphs	12/23/2011	32	%	14-46	Raleigh Medical Group, P.A.
Monocytes	12/23/2011	10	%	4-13	Raleigh Medical Group, P.A.
Eos	12/23/2011	2	%	0-7	Raleigh Medical Group, P.A.
Basos	12/23/2011	1	%	0-3	Raleigh Medical Group, P.A.
Neutrophils (Absolute)	12/23/2011	3.8	x10E3/uL	1.8-7.8	Raleigh Medical Group, P.A.
Lymphs (Absolute)	12/23/2011	2.2	x10E3/uL	0.7-4.5	Raleigh Medical Group, P.A.
Monocytes(Absolute)	12/23/2011	0.7	x10E3/uL	0.1-1.0	Raleigh Medical Group, P.A.
Eos (Absolute)	12/23/2011	0.1	x10E3/uL	0.0-0.4	Raleigh Medical Group, P.A.
Baso (Absolute)	12/23/2011	0.1	x10E3/uL	0.0-0.2	Raleigh Medical Group, P.A.
Immature Granulocytes	12/23/2011	0	%	0-2	Raleigh Medical Group, P.A.
Immature Grans (Abs)	12/23/2011	0.0	x10E3/uL	0.0-0.1	Raleigh Medical Group, P.A.

Order: Lipid Panel (LDL:HDL ratio) (80061) Ordered On: 03/22/2016

Notes:

PATIENT WAS FASTING
 PERFORMED BY: BN LabCorp Burlington
 1447 York Court
 Burlington NC 272153361
 8007624344

Name	Resulted On	Value	Units	Range	Source
Cholesterol, Total	4/1/2016	166	mg/dL	100-199	Raleigh Medical Group, P.A.
Triglycerides	4/1/2016	96	mg/dL	0-149	Raleigh Medical Group, P.A.
VLDL Cholesterol Cal	4/1/2016	19	mg/dL	5-40	Raleigh Medical Group, P.A.
HDL Cholesterol	4/1/2016	43	mg/dL	>39	Raleigh Medical Group, P.A.

Notes:

According to ATP-III Guidelines, HDL-C >59 mg/dL is considered a negative risk factor for CHD.

According to ATP-III Guidelines, HDL-C >59 mg/dL is considered a negative risk factor for CHD.

LDL/HDL Ratio	4/1/2016	2.4	ratio units	0.0-3.6	Raleigh Medical Group, P.A.
---------------	----------	-----	-------------	---------	-----------------------------

Notes:

LDL/HDL Ratio		
Men	Women	
1/2 Avg.Risk	1.0	1.5
Avg.Risk	3.6	3.2
2X Avg.Risk	6.2	5.0
3X Avg.Risk	8.0	6.1

LDL/HDL Ratio		
Men	Women	
1/2 Avg.Risk	1.0	1.5
Avg.Risk	3.6	3.2
2X Avg.Risk	6.2	5.0
3X Avg.Risk	8.0	6.1

LDL Cholesterol Calc	4/1/2016	104	mg/dL	0-99	Raleigh Medical Group, P.A.
----------------------	----------	-----	-------	------	-----------------------------

Order: Comprehensive Metabolic Panel with eGFR (80053) Ordered On: 12/20/2011

Notes:

PATIENT WAS FASTING
 PERFORMED BY: BN LabCorp Burlington
 1447 York Court
 Burlington NC 272153361
 8007624344

Name	Resulted On	Value	Units	Range	Source
Glucose, Serum	12/23/2011	89	mg/dL	65-99	Raleigh Medical Group, P.A.
BUN	12/23/2011	13	mg/dL	8-27	Raleigh Medical Group, P.A.

Name	Resulted On	Value	Units	Range	Source
Creatinine, Serum	12/23/2011	0.97	mg/dL	0.76-1.27	Raleigh Medical Group, P.A.
BUN/Creatinine Ratio	12/23/2011	13		10-22	Raleigh Medical Group, P.A.
Potassium, Serum	12/23/2011	3.8	mmol/L	3.5-5.2	Raleigh Medical Group, P.A.
Chloride, Serum	12/23/2011	98	mmol/L	97-108	Raleigh Medical Group, P.A.
Carbon Dioxide, Total	12/23/2011	25	mmol/L	20-32	Raleigh Medical Group, P.A.
Calcium, Serum	12/23/2011	9.0	mg/dL	8.6-10.2	Raleigh Medical Group, P.A.
Protein, Total, Serum	12/23/2011	6.9	g/dL	6.0-8.5	Raleigh Medical Group, P.A.
Albumin, Serum	12/23/2011	4.4	g/dL	3.6-4.8	Raleigh Medical Group, P.A.
Globulin, Total	12/23/2011	2.5	g/dL	1.5-4.5	Raleigh Medical Group, P.A.
Sodium, Serum	12/23/2011	139	mmol/L	134-144	Raleigh Medical Group, P.A.

Notes:

Please note reference interval change

Please note reference interval change

A/G Ratio	12/23/2011	1.8		1.1-2.5	Raleigh Medical Group, P.A.
Bilirubin, Total	12/23/2011	0.5	mg/dL	0.0-1.2	Raleigh Medical Group, P.A.
Alkaline Phosphatase, S	12/23/2011	70	IU/L	25-160	Raleigh Medical Group, P.A.
AST (SGOT)	12/23/2011	19	IU/L	0-40	Raleigh Medical Group, P.A.
ALT (SGPT)	12/23/2011	19	IU/L	0-55	Raleigh Medical Group, P.A.

Order: LIPID PANEL (80061) Ordered On: 03/23/2015**Notes:**

PERFORMED BY: 01 LabCorp Burlington
 1447 York Court
 Burlington NC 272153361
 8007624344

Name	Resulted On	Value	Units	Range	Source
Cholesterol, Total	3/26/2015	161	mg/dL	100-199	Raleigh Medical Group, P.A.
Triglycerides	3/26/2015	85	mg/dL	0-149	Raleigh Medical Group, P.A.
VLDL Cholesterol Cal	3/26/2015	17	mg/dL	5-40	Raleigh Medical Group, P.A.
LDL Cholesterol Calc	3/26/2015	107	mg/dL	0-99	Raleigh Medical Group, P.A.
HDL Cholesterol	3/26/2015	37	mg/dL	>39	Raleigh Medical Group, P.A.

Notes:

According to ATP-III Guidelines, HDL-C >59 mg/dL is considered a negative risk factor for CHD.

According to ATP-III Guidelines, HDL-C >59 mg/dL is considered a negative risk factor for CHD.

Order: Metabolic Panel, Comprehensive (80053) Ordered On: 03/11/2014**Notes:**

PERFORMED BY: 01 LabCorp Burlington
 1447 York Court
 Burlington NC 272153361
 8007624344

Name	Resulted On	Value	Units	Range	Source
Glucose, Serum	3/15/2014	87	mg/dL	65-99	Raleigh Medical Group, P.A.
BUN	3/15/2014	12	mg/dL	8-27	Raleigh Medical Group, P.A.
Creatinine, Serum	3/15/2014	1.03	mg/dL	0.76-1.27	Raleigh Medical Group, P.A.
BUN/Creatinine Ratio	3/15/2014	12		10-22	Raleigh Medical Group, P.A.
Sodium, Serum	3/15/2014	138	mmol/L	134-144	Raleigh Medical Group, P.A.
Potassium, Serum	3/15/2014	4.4	mmol/L	3.5-5.2	Raleigh Medical Group, P.A.
Chloride, Serum	3/15/2014	98	mmol/L	97-108	Raleigh Medical Group, P.A.
Carbon Dioxide, Total	3/15/2014	28	mmol/L	19-28	Raleigh Medical Group, P.A.
Calcium, Serum	3/15/2014	9.6	mg/dL	8.6-10.2	Raleigh Medical Group, P.A.
Protein, Total, Serum	3/15/2014	6.9	g/dL	6.0-8.5	Raleigh Medical Group, P.A.
Albumin, Serum	3/15/2014	4.4	g/dL	3.6-4.8	Raleigh Medical Group, P.A.
Globulin, Total	3/15/2014	2.5	g/dL	1.5-4.5	Raleigh Medical Group, P.A.
A/G Ratio	3/15/2014	1.8		1.1-2.5	Raleigh Medical Group, P.A.

Name	Resulted On	Value	Units	Range	Source
Bilirubin, Total	3/15/2014	0.7	mg/dL	0.0-1.2	Raleigh Medical Group, P.A.
Alkaline Phosphatase, S	3/15/2014	61	IU/L	39-117	Raleigh Medical Group, P.A.
AST (SGOT)	3/15/2014	16	IU/L	0-40	Raleigh Medical Group, P.A.
ALT (SGPT)	3/15/2014	21	IU/L	0-44	Raleigh Medical Group, P.A.

Order: Metabolic Panel (14), Comprehensive w/o GFR (80053) Ordered On: 10/09/2019

Notes:

PATIENT WAS FASTING
PERFORMED BY: BN LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

Name	Resulted On	Value	Units	Range	Source
Glucose	10/22/2019	92	mg/dL	65-99	Raleigh Medical Group, P.A.
BUN	10/22/2019	14	mg/dL	8-27	Raleigh Medical Group, P.A.
Creatinine	10/22/2019	1.14	mg/dL	0.76-1.27	Raleigh Medical Group, P.A.
BUN/Creatinine Ratio	10/22/2019	12		10-24	Raleigh Medical Group, P.A.
Sodium	10/22/2019	138	mmol/L	134-144	Raleigh Medical Group, P.A.
Potassium	10/22/2019	4.1	mmol/L	3.5-5.2	Raleigh Medical Group, P.A.
Chloride	10/22/2019	97	mmol/L	96-106	Raleigh Medical Group, P.A.
Carbon Dioxide, Total	10/22/2019	25	mmol/L	20-29	Raleigh Medical Group, P.A.
Calcium	10/22/2019	9.6	mg/dL	8.6-10.2	Raleigh Medical Group, P.A.
Protein, Total	10/22/2019	6.7	g/dL	6.0-8.5	Raleigh Medical Group, P.A.
Albumin	10/22/2019	4.5	g/dL	3.5-4.8	Raleigh Medical Group, P.A.
Globulin, Total	10/22/2019	2.2	g/dL	1.5-4.5	Raleigh Medical Group, P.A.
A/G Ratio	10/22/2019	2.0		1.2-2.2	Raleigh Medical Group, P.A.
Bilirubin, Total	10/22/2019	0.7	mg/dL	0.0-1.2	Raleigh Medical Group, P.A.
Alkaline Phosphatase	10/22/2019	56	IU/L	39-117	Raleigh Medical Group, P.A.
AST (SGOT)	10/22/2019	20	IU/L	0-40	Raleigh Medical Group, P.A.
ALT (SGPT)	10/22/2019	19	IU/L	0-44	Raleigh Medical Group, P.A.

Order: TISSUE EXAM BY PATHOLOGIST, LVL IV (88305) Ordered On: 03/08/2013

Name	Resulted On	Value	Units	Range	Source
TISSUE EXAM BY PATHOLOGIST, LVL IV	3/8/2013	see Pathology report			Raleigh Medical Group, P.A.

Order: PSA Serum 010322 (84153) Ordered On: 01/15/2013

Notes:

PERFORMED BY: 01 LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

Name	Resulted On	Value	Units	Range	Source
Prostate Specific Ag, Serum	1/19/2013	0.7	ng/mL	0.0-4.0	Raleigh Medical Group, P.A.

Notes:

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater.

Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory

Name Resulted On Value Units Range Source
 PSA value 0.2 ng/mL or greater.
 Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

Order: CBC WITH DIFF/PLT COUNT/AUTOMATED (85025) Ordered On: 01/15/2013

Notes:

PERFORMED BY: 01 LabCorp Burlington
 1447 York Court
 Burlington NC 272153361
 8007624344

Name	Resulted On	Value	Units	Range	Source
WBC	1/19/2013	6.4	x10E3/uL	4.0-10.5	Raleigh Medical Group, P.A.
RBC	1/19/2013	4.76	x10E6/uL	4.14-5.80	Raleigh Medical Group, P.A.
Hemoglobin	1/19/2013	14.4	g/dL	12.6-17.7	Raleigh Medical Group, P.A.
Hematocrit	1/19/2013	42.2	%	37.5-51.0	Raleigh Medical Group, P.A.
MCV	1/19/2013	89	fL	79-97	Raleigh Medical Group, P.A.
MCH	1/19/2013	30.3	pg	26.6-33.0	Raleigh Medical Group, P.A.
MCHC	1/19/2013	34.1	g/dL	31.5-35.7	Raleigh Medical Group, P.A.
RDW	1/19/2013	13.2	%	12.3-15.4	Raleigh Medical Group, P.A.
Platelets	1/19/2013	270	x10E3/uL	140-415	Raleigh Medical Group, P.A.
Neutrophils	1/19/2013	56	%	40-74	Raleigh Medical Group, P.A.
Lymphs	1/19/2013	31	%	14-46	Raleigh Medical Group, P.A.
Monocytes	1/19/2013	9	%	4-13	Raleigh Medical Group, P.A.
Eos	1/19/2013	3	%	0-7	Raleigh Medical Group, P.A.
Basos	1/19/2013	1	%	0-3	Raleigh Medical Group, P.A.
Neutrophils (Absolute)	1/19/2013	3.6	x10E3/uL	1.8-7.8	Raleigh Medical Group, P.A.
Lymphs (Absolute)	1/19/2013	2.0	x10E3/uL	0.7-4.5	Raleigh Medical Group, P.A.
Monocytes(Absolute)	1/19/2013	0.6	x10E3/uL	0.1-1.0	Raleigh Medical Group, P.A.
Eos (Absolute)	1/19/2013	0.2	x10E3/uL	0.0-0.4	Raleigh Medical Group, P.A.
Baso (Absolute)	1/19/2013	0.1	x10E3/uL	0.0-0.2	Raleigh Medical Group, P.A.
Immature Granulocytes	1/19/2013	0	%	0-2	Raleigh Medical Group, P.A.
Immature Grans (Abs)	1/19/2013	0.0	x10E3/uL	0.0-0.1	Raleigh Medical Group, P.A.

Order: LIPID PANEL (80061) Ordered On: 12/20/2011

Notes:

PATIENT WAS FASTING
 PERFORMED BY: BN LabCorp Burlington
 1447 York Court
 Burlington NC 272153361
 8007624344

Name	Resulted On	Value	Units	Range	Source
Cholesterol, Total	12/23/2011	194	mg/dL	100-199	Raleigh Medical Group, P.A.
Triglycerides	12/23/2011	103	mg/dL	0-149	Raleigh Medical Group, P.A.
VLDL Cholesterol Cal	12/23/2011	21	mg/dL	5-40	Raleigh Medical Group, P.A.
LDL Cholesterol Calc	12/23/2011	126	mg/dL	0-99	Raleigh Medical Group, P.A.
HDL Cholesterol	12/23/2011	47	mg/dL	>39	Raleigh Medical Group, P.A.

Notes:

According to ATP-III Guidelines, HDL-C >59 mg/dL is considered a negative risk factor for CHD.

According to ATP-III Guidelines, HDL-C >59 mg/dL is considered a negative risk factor for CHD.

Order: CBC WITH DIFF/PLT COUNT/AUTOMATED (85025) Ordered On: 10/04/2018

Notes:

PATIENT WAS FASTING
 PERFORMED BY: BN LabCorp Burlington
 1447 York Court

Burlington NC 272153361
8007624344

Name	Resulted On	Value	Units	Range	Source
WBC	10/17/2018	6.5	x10E3/uL	3.4-10.8	Raleigh Medical Group, P.A.
RBC	10/17/2018	4.58	x10E6/uL	4.14-5.80	Raleigh Medical Group, P.A.
Hemoglobin	10/17/2018	13.9	g/dL	13.0-17.7	Raleigh Medical Group, P.A.
Hematocrit	10/17/2018	40.7	%	37.5-51.0	Raleigh Medical Group, P.A.
MCV	10/17/2018	89	fL	79-97	Raleigh Medical Group, P.A.
MCH	10/17/2018	30.3	pg	26.6-33.0	Raleigh Medical Group, P.A.
MCHC	10/17/2018	34.2	g/dL	31.5-35.7	Raleigh Medical Group, P.A.
RDW	10/17/2018	13.4	%	12.3-15.4	Raleigh Medical Group, P.A.
Platelets	10/17/2018	245	x10E3/uL	150-379	Raleigh Medical Group, P.A.
Neutrophils	10/17/2018	53	%	Not Estab.	Raleigh Medical Group, P.A.
Lymphs	10/17/2018	33	%	Not Estab.	Raleigh Medical Group, P.A.
Monocytes	10/17/2018	11	%	Not Estab.	Raleigh Medical Group, P.A.
Eos	10/17/2018	2	%	Not Estab.	Raleigh Medical Group, P.A.
Basos	10/17/2018	1	%	Not Estab.	Raleigh Medical Group, P.A.
Neutrophils (Absolute)	10/17/2018	3.5	x10E3/uL	1.4-7.0	Raleigh Medical Group, P.A.
Lymphs (Absolute)	10/17/2018	2.1	x10E3/uL	0.7-3.1	Raleigh Medical Group, P.A.
Monocytes(Absolute)	10/17/2018	0.7	x10E3/uL	0.1-0.9	Raleigh Medical Group, P.A.
Eos (Absolute)	10/17/2018	0.1	x10E3/uL	0.0-0.4	Raleigh Medical Group, P.A.
Baso (Absolute)	10/17/2018	0.0	x10E3/uL	0.0-0.2	Raleigh Medical Group, P.A.
Immature Granulocytes	10/17/2018	0	%	Not Estab.	Raleigh Medical Group, P.A.
Immature Grans (Abs)	10/17/2018	0.0	x10E3/uL	0.0-0.1	Raleigh Medical Group, P.A.

Order: PSA (Medicare) (G0103) Ordered On: 10/04/2018

Notes:

PATIENT WAS FASTING
PERFORMED BY: BN LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

Name	Resulted On	Value	Units	Range	Source
Prostate Specific Ag, Serum	10/17/2018	0.9	ng/mL	0.0-4.0	Raleigh Medical Group, P.A.

Notes:

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater.

Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater.

Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

Order: CBC WITH DIFF/PLT COUNT/AUTOMATED (85025) Ordered On: 03/11/2014

Notes:

PERFORMED BY: 01 LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

Name	Resulted On	Value	Units	Range	Source
WBC	3/15/2014	5.6	x10E3/uL	3.4-10.8	Raleigh Medical Group, P.A.
RBC	3/15/2014	4.73	x10E6/uL	4.14-5.80	Raleigh Medical Group, P.A.
Hemoglobin	3/15/2014	14.4	g/dL	12.6-17.7	Raleigh Medical Group, P.A.
Hematocrit	3/15/2014	42.4	%	37.5-51.0	Raleigh Medical Group, P.A.
MCV	3/15/2014	90	fL	79-97	Raleigh Medical Group, P.A.
MCH	3/15/2014	30.4	pg	26.6-33.0	Raleigh Medical Group, P.A.
MCHC	3/15/2014	34.0	g/dL	31.5-35.7	Raleigh Medical Group, P.A.
RDW	3/15/2014	13.2	%	12.3-15.4	Raleigh Medical Group, P.A.
Platelets	3/15/2014	237	x10E3/uL	155-379	Raleigh Medical Group, P.A.
Neutrophils	3/15/2014	55	%	40-74	Raleigh Medical Group, P.A.
Lymphs	3/15/2014	33	%	14-46	Raleigh Medical Group, P.A.
Monocytes	3/15/2014	9	%	4-12	Raleigh Medical Group, P.A.
Eos	3/15/2014	2	%	0-5	Raleigh Medical Group, P.A.
Basos	3/15/2014	1	%	0-3	Raleigh Medical Group, P.A.
Neutrophils (Absolute)	3/15/2014	3.1	x10E3/uL	1.4-7.0	Raleigh Medical Group, P.A.
Lymphs (Absolute)	3/15/2014	1.8	x10E3/uL	0.7-3.1	Raleigh Medical Group, P.A.
Monocytes(Absolute)	3/15/2014	0.5	x10E3/uL	0.1-0.9	Raleigh Medical Group, P.A.
Eos (Absolute)	3/15/2014	0.1	x10E3/uL	0.0-0.4	Raleigh Medical Group, P.A.
Baso (Absolute)	3/15/2014	0.0	x10E3/uL	0.0-0.2	Raleigh Medical Group, P.A.
Immature Granulocytes	3/15/2014	0	%	0-2	Raleigh Medical Group, P.A.
Immature Grans (Abs)	3/15/2014	0.0	x10E3/uL	0.0-0.1	Raleigh Medical Group, P.A.

Order: METABOLIC PANEL, BASIC (80048) Ordered On: 02/01/2013

Notes:

PERFORMED BY: 01 LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

Name	Resulted On	Value	Units	Range	Source
Glucose, Serum	3/2/2013	88	mg/dL	65-99	Raleigh Medical Group, P.A.
BUN	3/2/2013	17	mg/dL	8-27	Raleigh Medical Group, P.A.
Creatinine, Serum	3/2/2013	0.96	mg/dL	0.76-1.27	Raleigh Medical Group, P.A.
BUN/Creatinine Ratio	3/2/2013	18		10-22	Raleigh Medical Group, P.A.
Sodium, Serum	3/2/2013	138	mmol/L	134-144	Raleigh Medical Group, P.A.
Potassium, Serum	3/2/2013	4.1	mmol/L	3.5-5.2	Raleigh Medical Group, P.A.
Chloride, Serum	3/2/2013	97	mmol/L	97-108	Raleigh Medical Group, P.A.
Carbon Dioxide, Total	3/2/2013	27	mmol/L	20-32	Raleigh Medical Group, P.A.
Calcium, Serum	3/2/2013	9.6	mg/dL	8.6-10.2	Raleigh Medical Group, P.A.

Order: TISSUE EXAM BY PATHOLOGIST, LVL IV (88305) Ordered On: 03/08/2013

Name	Resulted On	Value	Units	Range	Source
TISSUE EXAM BY PATHOLOGIST, LVL IV	3/8/2013	see Pathology report			Raleigh Medical Group, P.A.

Order: Written Authorization Ordered On: 12/22/2011

Notes:

PATIENT WAS FASTING
PERFORMED BY: BN LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

Name	Resulted On	Value	Units	Range	Source
Written Authorization	12/28/2011	Comment			Raleigh Medical Group, P.A.

Notes:

Written Authorization Received.
Authorization received from DEREK SCHRODER 12-28-2011
Logged by Latosha Bayron

Name Resulted On Value Units Range Source
 Written Authorization Received.
 Authorization received from DEREK SCHRODER 12-28-2011
 Logged by Latosha Bayron

Order: CBC WITH DIFF/PLT COUNT/AUTOMATED (85025) Ordered On: 03/23/2015

Notes:

PERFORMED BY: 01 LabCorp Burlington
 1447 York Court
 Burlington NC 272153361
 8007624344

Name	Resulted On	Value	Units	Range	Source
WBC	3/26/2015	5.6	x10E3/uL	3.4-10.8	Raleigh Medical Group, P.A.
RBC	3/26/2015	4.71	x10E6/uL	4.14-5.80	Raleigh Medical Group, P.A.
Hemoglobin	3/26/2015	14.1	g/dL	12.6-17.7	Raleigh Medical Group, P.A.
Hematocrit	3/26/2015	40.5	%	37.5-51.0	Raleigh Medical Group, P.A.
MCV	3/26/2015	86	fL	79-97	Raleigh Medical Group, P.A.
MCH	3/26/2015	29.9	pg	26.6-33.0	Raleigh Medical Group, P.A.
MCHC	3/26/2015	34.8	g/dL	31.5-35.7	Raleigh Medical Group, P.A.
RDW	3/26/2015	12.6	%	12.3-15.4	Raleigh Medical Group, P.A.
Platelets	3/26/2015	300	x10E3/uL	150-379	Raleigh Medical Group, P.A.
Neutrophils	3/26/2015	49	%		Raleigh Medical Group, P.A.
Lymphs	3/26/2015	36	%		Raleigh Medical Group, P.A.
Monocytes	3/26/2015	13	%		Raleigh Medical Group, P.A.
Eos	3/26/2015	1	%		Raleigh Medical Group, P.A.
Basos	3/26/2015	1	%		Raleigh Medical Group, P.A.
Neutrophils (Absolute)	3/26/2015	2.8	x10E3/uL	1.4-7.0	Raleigh Medical Group, P.A.
Lymphs (Absolute)	3/26/2015	2.0	x10E3/uL	0.7-3.1	Raleigh Medical Group, P.A.
Monocytes(Absolute)	3/26/2015	0.7	x10E3/uL	0.1-0.9	Raleigh Medical Group, P.A.
Eos (Absolute)	3/26/2015	0.1	x10E3/uL	0.0-0.4	Raleigh Medical Group, P.A.
Baso (Absolute)	3/26/2015	0.0	x10E3/uL	0.0-0.2	Raleigh Medical Group, P.A.
Immature Granulocytes	3/26/2015	0	%		Raleigh Medical Group, P.A.
Immature Grans (Abs)	3/26/2015	0.0	x10E3/uL	0.0-0.1	Raleigh Medical Group, P.A.

Order: PSA - TOTAL 010322 (84153) Ordered On: 03/23/2015

Notes:

PERFORMED BY: 01 LabCorp Burlington
 1447 York Court
 Burlington NC 272153361
 8007624344

Name	Resulted On	Value	Units	Range	Source
Prostate Specific Ag, Serum	3/26/2015	0.7	ng/mL	0.0-4.0	Raleigh Medical Group, P.A.

Notes:

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater.

Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater.

Values obtained with different assay methods or kits cannot be used

Name Resulted On Value Units Range Source
interchangeably. Results cannot be interpreted as absolute evidence
of the presence or absence of malignant disease.

Order: PSA, TOTAL 010322 (84153) Ordered On: 03/11/2014

Notes:

PERFORMED BY: 01 LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

Name	Resulted On	Value	Units	Range	Source
Prostate Specific Ag, Serum	3/15/2014	1.0	ng/mL	0.0-4.0	Raleigh Medical Group, P.A.

Notes:

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater.

Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater.

Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

Order: Comprehensive Metabolic Panel with eGFR (80053) Ordered On: 01/15/2013

Notes:

PERFORMED BY: 01 LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

Name	Resulted On	Value	Units	Range	Source
Glucose, Serum	1/19/2013	88	mg/dL	65-99	Raleigh Medical Group, P.A.
BUN	1/19/2013	13	mg/dL	8-27	Raleigh Medical Group, P.A.
Creatinine, Serum	1/19/2013	1.08	mg/dL	0.76-1.27	Raleigh Medical Group, P.A.
BUN/Creatinine Ratio	1/19/2013	12		10-22	Raleigh Medical Group, P.A.
Sodium, Serum	1/19/2013	139	mmol/L	134-144	Raleigh Medical Group, P.A.
Potassium, Serum	1/19/2013	4.1	mmol/L	3.5-5.2	Raleigh Medical Group, P.A.
Chloride, Serum	1/19/2013	100	mmol/L	97-108	Raleigh Medical Group, P.A.
Carbon Dioxide, Total	1/19/2013	25	mmol/L	20-32	Raleigh Medical Group, P.A.
Calcium, Serum	1/19/2013	9.2	mg/dL	8.6-10.2	Raleigh Medical Group, P.A.
Protein, Total, Serum	1/19/2013	6.7	g/dL	6.0-8.5	Raleigh Medical Group, P.A.
Albumin, Serum	1/19/2013	4.3	g/dL	3.6-4.8	Raleigh Medical Group, P.A.
Globulin, Total	1/19/2013	2.4	g/dL	1.5-4.5	Raleigh Medical Group, P.A.
A/G Ratio	1/19/2013	1.8		1.1-2.5	Raleigh Medical Group, P.A.
Bilirubin, Total	1/19/2013	0.5	mg/dL	0.0-1.2	Raleigh Medical Group, P.A.
Alkaline Phosphatase, S	1/19/2013	65	IU/L	25-160	Raleigh Medical Group, P.A.
AST (SGOT)	1/19/2013	14	IU/L	0-40	Raleigh Medical Group, P.A.
ALT (SGPT)	1/19/2013	20	IU/L	0-44	Raleigh Medical Group, P.A.

Order: Comprehensive Metabolic Panel with eGFR (80053) Ordered On: 03/23/2015

Notes:

PERFORMED BY: 01 LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

Name	Resulted On	Value	Units	Range	Source
Glucose, Serum	3/26/2015	93	mg/dL	65-99	Raleigh Medical Group, P.A.
BUN	3/26/2015	10	mg/dL	8-27	Raleigh Medical Group, P.A.
Creatinine, Serum	3/26/2015	1.06	mg/dL	0.76-1.27	Raleigh Medical Group, P.A.
Sodium, Serum	3/26/2015	135	mmol/L	134-144	Raleigh Medical Group, P.A.
Potassium, Serum	3/26/2015	4.1	mmol/L	3.5-5.2	Raleigh Medical Group, P.A.
Carbon Dioxide, Total	3/26/2015	25	mmol/L	18-29	Raleigh Medical Group, P.A.
Calcium, Serum	3/26/2015	9.5	mg/dL	8.6-10.2	Raleigh Medical Group, P.A.
Protein, Total, Serum	3/26/2015	6.5	g/dL	6.0-8.5	Raleigh Medical Group, P.A.
Albumin, Serum	3/26/2015	4.3	g/dL	3.6-4.8	Raleigh Medical Group, P.A.
Globulin, Total	3/26/2015	2.2	g/dL	1.5-4.5	Raleigh Medical Group, P.A.
A/G Ratio	3/26/2015	2.0		1.1-2.5	Raleigh Medical Group, P.A.
Bilirubin, Total	3/26/2015	0.6	mg/dL	0.0-1.2	Raleigh Medical Group, P.A.
BUN/Creatinine Ratio	3/26/2015	9		10-22	Raleigh Medical Group, P.A.
Chloride, Serum	3/26/2015	93	mmol/L	97-108	Raleigh Medical Group, P.A.
Alkaline Phosphatase, S	3/26/2015	61	IU/L	39-117	Raleigh Medical Group, P.A.
AST (SGOT)	3/26/2015	15	IU/L	0-40	Raleigh Medical Group, P.A.
ALT (SGPT)	3/26/2015	19	IU/L	0-44	Raleigh Medical Group, P.A.

Order: Lipid Panel (LDL:HDL ratio) (80061) Ordered On: 01/15/2013

Notes:

PERFORMED BY: 01 LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

Name	Resulted On	Value	Units	Range	Source
Cholesterol, Total	1/19/2013	195	mg/dL	100-199	Raleigh Medical Group, P.A.
VLDL Cholesterol Cal	1/19/2013	34	mg/dL	5-40	Raleigh Medical Group, P.A.
Triglycerides	1/19/2013	170	mg/dL	0-149	Raleigh Medical Group, P.A.
LDL Cholesterol Calc	1/19/2013	123	mg/dL	0-99	Raleigh Medical Group, P.A.
LDL/HDL Ratio	1/19/2013	3.2	ratio units	0.0-3.6	Raleigh Medical Group, P.A.
HDL Cholesterol	1/19/2013	38	mg/dL	>39	Raleigh Medical Group, P.A.

Notes:

According to ATP-III Guidelines, HDL-C >59 mg/dL is considered a negative risk factor for CHD.

According to ATP-III Guidelines, HDL-C >59 mg/dL is considered a negative risk factor for CHD.

Order: PSA, TOTAL 010322 (84153) Ordered On: 03/22/2016

Notes:

PATIENT WAS FASTING
PERFORMED BY: BN LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

Name	Resulted On	Value	Units	Range	Source
Prostate Specific Ag, Serum	4/1/2016	1.2	ng/mL	0.0-4.0	Raleigh Medical Group, P.A.

Notes:

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater.

Values obtained with different assay methods or kits cannot be used

Name	<p>Resulted On Value Units Range Source</p> <p>interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.</p> <p>Roche ECLIA methodology.</p> <p>According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater.</p> <p>Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.</p>
------	---

Order: Prostate-Specific Ag, Serum Ordered On: 12/22/2011

Notes:

PATIENT WAS FASTING
 PERFORMED BY: BN LabCorp Burlington
 1447 York Court
 Burlington NC 272153361
 8007624344

Name	Resulted On	Value	Units	Range	Source
Prostate Specific Ag, Serum	12/28/2011	0.8	ng/mL	0.0-4.0	Raleigh Medical Group, P.A.

Notes:

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater.

Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater.

Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

Order: PSA (Medicare) (G0103) Ordered On: 10/09/2019

Notes:

PATIENT WAS FASTING
 PERFORMED BY: BN LabCorp Burlington
 1447 York Court
 Burlington NC 272153361
 8007624344

Name	Resulted On	Value	Units	Range	Source
Prostate Specific Ag, Serum	10/22/2019	0.9	ng/mL	0.0-4.0	Raleigh Medical Group, P.A.

Notes:

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater.

Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

Name

Resulted On Value Units Range Source

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater.

Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

DISCLAIMER: This information is supplied from the patient's medical record via a patient portal. The medical provider is listed as the source. Items with a source of 'Patient-Entered' were added by the patient. This record may not be complete or up to date, and should not be used for providing medical advice. For an official copy of the individual's medical record, the patient (or custodian) must contact their medical provider.

Generated on 2/1/2023 11:33:21 AM by FollowMyHealth® (<http://www.followmyhealth.com>).